Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) CEO Acquires 50,000 Shares of Stock

MBX Biosciences, Inc. (NYSE:MBX) CEO P. Kent Hawryluk purchased 50,000 shares of MBX Biosciences stock in a transaction dated Tuesday, February 4th. The shares were bought at an average price of $10.69 per share, with a total value of $534,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 448,277 shares of the company’s stock, valued at approximately $4,792,081.13. This represents a 12.55 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MBX Biosciences Stock Up 0.7 %

Shares of NYSE:MBX opened at $12.34 on Friday. MBX Biosciences, Inc. has a 1-year low of $9.42 and a 1-year high of $27.50. The firm’s fifty day moving average is $16.10.

MBX Biosciences (NYSE:MBX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($2.78) earnings per share for the quarter, missing the consensus estimate of ($2.72) by ($0.06). On average, sell-side analysts predict that MBX Biosciences, Inc. will post -13.21 EPS for the current fiscal year.

Hedge Funds Weigh In On MBX Biosciences

Several institutional investors and hedge funds have recently modified their holdings of MBX. Rhumbline Advisers purchased a new stake in shares of MBX Biosciences during the fourth quarter valued at $175,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of MBX Biosciences during the third quarter valued at $278,000. Point72 Asset Management L.P. purchased a new stake in shares of MBX Biosciences during the third quarter valued at $405,000. Barclays PLC purchased a new stake in shares of MBX Biosciences during the third quarter valued at $426,000. Finally, Geode Capital Management LLC purchased a new stake in shares of MBX Biosciences during the third quarter valued at $579,000.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.